Abstract
Nephroangiosclerosis (NAS) is a major cause of progressive renal insufficiency. Hypertension is very important in the causation of NAS but other factors such as race, age, metabolic variables, and genetics play a pathogenic and prognostic role. A multifactorial treatment strategy, including antihypertensive, lipid-lowering and anti-platelet agents, could improve cardiovascular and renal outcomes in patients with vascular nephropathy.
Keywords: Nephroangiosclerosis, vascular nephropathy, hypertension, renal failure, statins
Current Vascular Pharmacology
Title: Nephroangiosclerosis and Its Pharmacological Approach
Volume: 9 Issue: 2
Author(s): Rosario Cianci, Biagio Barbano, Paola Martina, Antonietta Gigante, Lelio Polidori, Silvia Lai, Giada Ascoli, Irene De Francesco, Domenico Di Donato, Giorgio Fuiano and Alessandro Zuccala
Affiliation:
Keywords: Nephroangiosclerosis, vascular nephropathy, hypertension, renal failure, statins
Abstract: Nephroangiosclerosis (NAS) is a major cause of progressive renal insufficiency. Hypertension is very important in the causation of NAS but other factors such as race, age, metabolic variables, and genetics play a pathogenic and prognostic role. A multifactorial treatment strategy, including antihypertensive, lipid-lowering and anti-platelet agents, could improve cardiovascular and renal outcomes in patients with vascular nephropathy.
Export Options
About this article
Cite this article as:
Cianci Rosario, Barbano Biagio, Martina Paola, Gigante Antonietta, Polidori Lelio, Lai Silvia, Ascoli Giada, De Francesco Irene, Di Donato Domenico, Fuiano Giorgio and Zuccala Alessandro, Nephroangiosclerosis and Its Pharmacological Approach, Current Vascular Pharmacology 2011; 9 (2) . https://dx.doi.org/10.2174/157016111794519309
DOI https://dx.doi.org/10.2174/157016111794519309 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Measurements of Thermodynamic Acid Dissociation Constants for Three HMG-CoA Reductase Inhibitors by using RPLC and Study of Validation in Pharmaceutical Tablets
Current Pharmaceutical Analysis PPARγ in Angiogenesis and Vascular Development
Current Angiogenesis (Discontinued) Effect of Intranasal Administration of Galanin-like Peptide (GALP) on Body Weight and Hepatic Lipids Accumulation in Mice with Diet-induced Obesity
Current Pharmaceutical Design Protein-Tyrosine Phosphatase 1B as a Potential Drug Target for Obesity
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Phytoestrogen-Rich Dietary Supplements in Anti-Atherosclerotic Therapy in Postmenopausal Women
Current Pharmaceutical Design Serum Amyloid A and Its Potential Physiological / Pathological Functions - an Overview of Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Metformin Beyond Diabetes: New Life for an Old Drug
Current Diabetes Reviews Many Drugs and Phytochemicals Can Be Activated to Biological Reactive Intermediates
Current Drug Metabolism Management of Measurable Variable Cardiovascular Disease' Risk Factors
Current Cardiology Reviews The Current Indications and the Benefits of Combining a β3-Agonist with an Anticholinergic for the Treatment of OAB
Current Drug Targets Co-ultraPEALut: Role in Preclinical and Clinical Delirium Manifestations
CNS & Neurological Disorders - Drug Targets C-reactive Protein, Infection, and Outcome After Acute Ischemic Stroke: A Registry and Systematic Review
Current Neurovascular Research Emerging Potential of Natural Products as an Alternative Strategy to Pharmacological Agents Used Against Metabolic Disorders
Current Drug Metabolism Angiotensin II Receptor Blocker as an Inverse Agonist: A Current Perspective
Current Hypertension Reviews Integrative Analysis of Whole-genome Expression Profiling and Regulatory Network Identifies Novel Biomarkers for Insulin Resistance in Leptin Receptor-deficient Mice
Medicinal Chemistry Molecular Signals Elicited by GPCR Agonists in Hypertension, Cardiovascular Remodeling: Are MMPs and ADAMs Elusive Therapeutic Targets?
Current Hypertension Reviews Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Dexmedetomidine Use in General Anaesthesia
Current Drug Targets Change in Quality of Life of OSAHS Patients with Minimally Invasive Surgery or CPAP Therapy: A 2-year Retrospective, Single-center Parallel-group Study
Current Molecular Medicine